Every Form 4 that Fortress Biotech, Inc. (FBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIO filings page.
Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 1,190 shares of common stock at $1.819 per share on October 1, 2026, under the company's Employee Stock Purchase Plan. The acquisition was voluntarily reported and was exempt under Rule 16b-3(d) and Rule 16b-3(c); no Rule 10b5-1 plan is reported. His reported holdings after the acquisition were 1,652,761 shares, including 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
Jin David reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. Chief Financial Officer Jin David reported receiving an equity compensation grant of 400,000 restricted stock units, each representing one share of common stock. The units vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his continued service.
After this award, his reported holdings total 1,651,571 shares of common stock, including 1,230,000 shares underlying previously granted deferred restricted stock units. The transaction reflects a grant or award, not an open-market purchase.
Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 2,967 shares of common stock at $2.176 per share through the company’s Employee Stock Purchase Plan. This grant was reported as exempt under Rule 16b-3(d) and Rule 16b-3(c). After the transaction, he holds 1,251,571 shares in total, including 1,230,000 shares underlying deferred restricted stock units, so the new purchase represents a small portion of his overall position.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.
Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.
WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.